文献速递心力衰竭与心肌病

Acoramidis 对 ATTR-CM 患者心衰相关健康状况的影响:ATTRibute-CM 随机试验二次分析

Effect of Acoramidis on Heart Failure-Related Health Status: A Secondary Analysis of the ATTRibute-CM Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2026-01-01

本研究基于 ATTRibute-CM 随机临床试验的二次分析,纳入 611 例转甲状腺素蛋白淀粉样变心肌病(ATTR-CM)成人患者,比较 acoramidis 800 mg 每日两次与安慰剂治疗 30 个月的效果。结果显示,acoramidis 组 KCCQ-OS 评分较安慰剂组显著改善,组间最小二乘均值差为 9.9 分。第 30 个月时,acoramidis 组达到「存活且未恶化」「存活且良好」「存活且更好」的患者比例均显著高于安慰剂组。

要点

  • Acoramidis 治疗 30 个月显著延缓 ATTR-CM 患者心衰相关健康状况的下降。
  • 第 30 个月 KCCQ-OS 组间最小二乘均值差为 9.9 分,具有临床意义。
  • 「存活且未恶化」的需治疗人数为 6 例,提示疾病轨迹获得有临床意义的改善。

核心结论

  • 在 ATTR-CM 患者中,与安慰剂相比,acoramidis 显著延缓心衰相关健康状况的下降,提示具有以患者为中心的获益和疾病轨迹的临床相关改善。

研究设计与样本

  • ATTRibute-CM 为一项 3 期、多中心、国际、安慰剂对照随机临床试验,于 2019 年 4 月至 2023 年 5 月开展。
  • 纳入 ATTR-CM 成人患者,611 例进入改良意向治疗分析,其中 acoramidis 组 409 例,安慰剂组 202 例。
  • 干预方案为 acoramidis 盐酸盐 800 mg 或安慰剂,每日两次,持续 30 个月。
  • 主要分析采用重复测量混合效应模型,评估 30 个月内 KCCQ-OS 的最小二乘均值差异。

主要发现

  • 总体平均年龄为 77.2 岁,女性 56 例(9.2%)。基线 KCCQ-OS 均值在 acoramidis 组为 71.7 分,安慰剂组为 70.5 分。
  • 第 30 个月时,acoramidis 组较安慰剂组的 KCCQ-OS 最小二乘均值差为 9.9 分(95% CI,6.0-13.9;P < .001)。
  • 第 30 个月时,acoramidis 组 171 例(47%)达到「存活且未恶化」,安慰剂组 56 例(30%),比值比为 2.1(95% CI,1.4-3.1;P < .001),需治疗人数为 6。
  • acoramidis 组「存活且良好」168 例(46%)对比安慰剂组 59 例(31%),比值比为 1.9(95% CI,1.3-2.8;P < .001),需治疗人数为 7。
  • acoramidis 组「存活且更好」93 例(25%)对比安慰剂组 26 例(14%),比值比为 2.1(95% CI,1.3-3.4;P = .002),需治疗人数为 9。

关键数值与推荐

  • 「存活且未恶化」定义为 KCCQ-OS 较基线下降小于 5 分。
  • 「存活且良好」定义为 KCCQ-OS 大于 60 分且较基线下降小于 10 分。
  • 「存活且更好」定义为 KCCQ-OS 较基线增加大于 5 分。
  • 预设次要终点为 30 个月内 KCCQ-OS 的最小二乘均值差异。

临床怎么用

  • 对于 ATTR-CM 患者,acoramidis 治疗 30 个月可带来具有临床意义的心衰相关健康状况获益。
  • 「存活且未恶化」需治疗人数为 6 例,提示在临床实践中每治疗 6 例患者可有 1 例额外获益。

局限性

  • 本研究为二次分析,第 30 个月「存活且未恶化」「存活且良好」「存活且更好」的分析为事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In patients with transthyretin amyloid cardiomyopathy (ATTR-CM), acoramidis achieves near-complete (≥90%) transthyretin stabilization and reduces mortality and cardiovascular-related hospitalizations; however, its effect on patient-reported health status has not been comprehensively described. OBJECTIVE: To evaluate the effect of acoramidis on heart failure (HF)-related health status as assessed by the Kansas City Cardiomyopathy Questionnaire Overall Summary score (KCCQ-OS) in patients with ATTR-CM. DESIGN, SETTING, AND PARTICIPANTS: ATTRibute-CM was a phase 3, multicenter, international, placebo-controlled randomized clinical trial conducted from April 2019 through May 2023. Adults with ATTR-CM were eligible for inclusion. Data were analyzed from July 2023 through November 2023. INTERVENTIONS: Acoramidis hydrochloride (800 mg) or placebo twice daily for 30 months. MAIN OUTCOMES AND MEASURES: The prespecified secondary outcome was least-squares mean (LSM) difference in KCCQ-OS over 30 months, analyzed using a mixed-effects model for repeated measures. Post hoc analysis at month 30 included being "alive and not worse" (KCCQ-OS <5-point decrease from baseline), "alive and well" (KCCQ-OS >60 and <10-point decrease from baseline), and "alive and better" (KCCQ-OS >5-point increase from baseline). RESULTS: Among 632 adults with ATTR-CM enrolled, 611 were included in the modified intention-to-treat population. Overall mean (SD) age was 77.2 (6.6) years, and 56 participants (9.2%) were female. Baseline mean (SD) KCCQ-OSs were 71.7 (19.4) and 70.5 (20.7) in the acoramidis (n = 409) and placebo (n = 202) groups, respectively. At month 30, a statistically significant, clinically meaningful treatment benefit was observed for acoramidis vs placebo (LSM difference, 9.9; 95% CI, 6.0-13.9; P < .001). At month 30 (acoramidis: 367; placebo: 188), 171 acoramidis recipients (47%) were "alive and not worse" vs 56 placebo recipients (30%) (odds ratio, 2.1; 95% CI, 1.4-3.1; P < .001; number needed to treat [NNT] = 6). More acoramidis recipients (168 [46%]) were "alive and well" vs placebo (59 [31%]) (odds ratio, 1.9; 95% CI, 1.3-2.8; P < .001; NNT = 7). Similarly, 93 acoramidis recipients (25%) were "alive and better" vs 26 placebo recipients (14%) (odds ratio, 2.1; 95% CI, 1.3-3.4; P = .002; NNT = 9). CONCLUSIONS AND RELEVANCE: In this secondary analysis of the ATTRibute-CM randomized clinical trial, in patients with ATTR-CM, acoramidis significantly attenuated the decline in HF-related health status compared with placebo. These results suggest meaningful patient-centered benefits and clinically relevant modification of disease trajectory with acoramidis. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03860935.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Sherrod, Fontana, Gillmore, et al. Effect of Acoramidis on Heart Failure-Related Health Status: A Secondary Analysis of the ATTRibute-CM Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 42525404. doi:10.1001/jamacardio.2026.2413

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。